Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Jacqueline V. Aredo(Stanford University), Heather A. Wakelee(Palo Alto Institute), Jessica A. Hellyer(Montrose Center), Tariq Abuali(City Of Hope National Medical Center), Billy W. Loo(Princess Margaret Cancer Centre), Isa Mambetsariev(City Of Hope National Medical Center), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Joel W. Neal(Stanford Medicine), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Sukhmani K. Padda(Stanford University), Arya Amini(City Of Hope National Medical Center), Summer S. Han(Stanford Health Care), Jonathan W. Riess(University of California Davis Medical Center), Maximilian Diehn(Stanford University), Elwyn C. Cabebe(Stanford Health Care), Ravi Salgia(City Of Hope National Medical Center)
Cited by 131
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k